Fig. 7. Darapladib enhances the antitumour activity of PACMA31 by accelerating ferroptosis.

a Western blot showing the band shift of GPX4 after PACMA31 treatment. Experiments repeated three times. b Cellular thermal shift assay showing the thermal stabilisation of GPX4 in cells treated with PACMA31. Experiments were repeated three times. c Relative viability and IC₅₀ value of Hs746T, SNU-484, and H1299 cells treated with PACMA31. The data are presented as the means ± SDs (Hs746T: n = 6, SNU-484: n = 4, H1299: n = 3 independent experiments). d, e Relative viability of Hs746T, SNU-484, YCC-16 and H1299 cells treated with PACMA31 and/or 2 µM darapladib in the presence or absence of Fer-1 for 20 h. The data are presented as the means ± SDs (n = 3–6 independent experiments, the significance of the results was assessed using a two-tailed Student’s t test). f Relative viability of Hs746T cells treated with PACMA31 and/or various concentrations of darapladib. The data are presented as the means ± SDs (n = 3 independent experiments). g, h SNU-484 cells were injected subcutaneously into nude mice; 14 days after inoculation, the mice were treated with 10 mg/kg PACMA31, 10 mg/kg darapladib, and 10 mg/kg fer-1 via intraperitoneal injections every 3 days as indicated. Tumour growth is shown in (g), and tumours are shown in (h). Each treatment group consisted of 5–7 mice. The data are presented as the means ± SDs, the significance of the results was assessed using a two-tailed Student’s t test). Exact p values provided as source data. Source data are provided as a source data file.